0TDD Stock Chart & Stats
$48.80
$1.20(2.41%)
At close: 4:00 PM EDT
$48.80
$1.20(2.41%)
Day’s Range― - ―
52-Week Range$35.09 - $64.35
Previous CloseN/A
Volume53.81K
Average Volume (3M)71.82K
Market Cap
$209.64B
Enterprise Value$227.20K
Total Cash (Recent Filing)$44.98B
Total Debt (Recent Filing)$140.13B
Price to Earnings (P/E)11.2
Beta0.83
Next Earnings
Nov 04, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.23
Shares Outstanding3,390,128,000
10 Day Avg. Volume75,772
30 Day Avg. Volume71,824
Financial Highlights & Ratios
PEG Ratio8.16
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$44.33Price Target Upside-9.15% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)3.28
Revenue Forecast (FY)$44.45B
Bulls Say, Bears Say
Bulls Say
GLP‑1/Obesity Market LeadershipLeading NBRx share (~65%) and rapid oral Wegovy adoption create a durable commercial moat: formulary parity with major PBMs, strong telehealth distribution, and high GLP‑1 penetration broaden patient access and reduce competitor entry advantages over the next 2–6 months.
Exceptional Profitability & Revenue MomentumVery high margins and near‑term revenue acceleration reflect scalable manufacturing and pricing power in core franchises. Sustained profitability supports reinvestment in R&D, commercial expansion, and shareholder returns, underpinning long‑term earnings resilience despite cyclical headwinds.
Strong Operating Cash Flow & Capital ReturnRobust operating cash generation, even with lower cash conversion, funds significant buybacks and dividends while financing R&D and launches. This cash flexibility supports capital allocation and signal of management discipline that bolsters balance sheet utility over multiple quarters.
Bears Say
Rapid Debt IncreaseSharp debt growth materially increases leverage and reduces financial flexibility. If pricing, reimbursement or product cycles weaken, higher interest and refinancing risk could constrain investment or force slower buybacks, making the capital structure more sensitive to cyclical shocks.
Pricing & Reimbursement PressureSustained downward pressure from payer actions, policy (e.g., MFN assumptions), and reduced Medicaid obesity coverage are structural threats to realized pricing. Lower net prices compress margins and limit revenue scalability even as volumes rise, weakening medium‑term profit outlook.
Material R&D Setback (ZEUS Failure)A failed large cardiovascular outcome trial reduces expected pipeline diversification and triggers impairments, increasing reliance on GLP‑1 franchises. This raises execution risk for long‑term growth and could force reallocation of R&D resources toward salvage or alternate programs.
Novo Nordisk News
0TDD FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest share price was $35.09 and its highest was $64.35 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $209.64B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 88 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 04, 2026. The company reported $0.955 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.185.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.78.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.955 in its last earnings report, beating expectations of $0.77. Following the earnings report the stock price went up 1.832%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in GB:0TDD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.33 (-9.15% Downside)
$44.33 (-9.15% Downside)
Blogger Sentiment
Bullish
GB:0TDD Sentiment 77%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 65%
Bearish news 35%
Bearish news 35%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.68%
12-Months-Change
Fundamentals
Return on Equity
3.56%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
0TDD Company Deck
0TDD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights very strong commercial and clinical momentum—especially for the Wegovy franchise (oral and high‑dose launches), positive pivotal and Phase II readouts (Etavopivat, UBT251), significant prescription uptake and clear execution on launches and shareholder returns. However, these commercial and R&D successes are balanced by meaningful near‑term financial headwinds: adjusted sales and operating profit declines, margin pressure from lower realized prices, pricing and reimbursement pressures (U.S. and international), guidance implying negative group growth for 2026, and supply/inventory nuances. Overall, product and pipeline momentum is robust, but the company faces material pricing and market access challenges that temper the near‑term financial outlook.View all GB:0TDD earnings summaries0TDD Stock 12 Month Forecast
Average Price Target
$44.33
▼(-9.15% Downside)